Study S002365

Combination Therapy With Tirzepatide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07635953
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 296
Start: 2026-07-01
Primary completion: 2029-07-01
Lead sponsor: Sun Yat-sen University
Conditions: Diabetes Mellitus
Interventions: DRUG:Group A (triple combination intensive therapy group); DRUG:Group B (standard therapy group)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Diabetic remission rate [6 months after discontinuation of medication]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.